Treating early psychosis: Who, what, and when?

Dialogues in Clinical Neuroscience

Volumn 7, Issue 1, 2005, Pages 39-49

  Cornblatt, Barbara A ^a,b,c   Auther, Andrea M ^b  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c RAP Program   (United States)

Author keywords

Early identification; Prevention; Prodrome; Psychosis; Schizophrenia; Treatment

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; RISPERIDONE;

AUSTRALIA; BEHAVIOR THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE THERAPY; DISEASE MODEL; EARLY DIAGNOSIS; EDUCATION PROGRAM; HUMAN; PATIENT EDUCATION; PSYCHOSIS; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SYMPTOMATOLOGY; TREATMENT OUTCOME; TREATMENT PLANNING;

EARLY DIAGNOSIS; HUMANS; PSYCHOTIC DISORDERS; RANDOMIZED CONTROLLED TRIALS; TIME FACTORS;

EID: 17444413737     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Morrison AP, Bentall RP, French P, et al. Randomised controlled trial of early detection and cognitive therapy for preventing transition to psychosis in high-risk individuals. Study design and interim analysis of transition rate and psychological risk factors. Br J Psychiatry. 2002;43(suppl):S78-S84.
2. Bassett AS, Chow EW, O'Neill S, Brzustowicz LM. Genetic insights into the neurodevelopmental hypothesis of schizophrenia. Schizophr Bull. 2001;27:417-430.
3. Cannon TD, van Erp TG, Bearden CE, et al. Early and late neurodevelopmental influences in the prodrome to schizophrenia: contributions of genes, environment, and their interactions. Schizophr Bull. 2003;29:653-669.
4. Cornblatt BA. The schizophrenia prodrome: promise for prevention. Dialogues Clin Neurosci. 2001;3:93-98.
5. Cornblatt BA, Lencz T, Obuchowski M. The schizophrenia prodrome: treatment and high-risk perspectives. Schizophr Res. 2002;54:177-186.
6. Cornblatt BA, Lencz T, Smith CW, Auther A. Treatment of the schizophrenia prodrome. In: Stone WS, Faraone SV, Tsuang MT, eds. Early Clinical Intervention and Prevention of Schizophrenia, Totowa, NJ: Humana Press; 2003.
7. Davidson M, Reichenberg A, Rabinowitz J, Weiser M, Kaplan Z, Mark M. Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents. Am J Psychiatry. 1999;156:1328-1335.
8. Tsuang MT. Genes, environment, and mental health wellness. Am J Psychiatry. 2000;157:489-491.
9. Tsuang MT, Stone WS, Faraone SV. Toward reformulating the diagnosis of schizophrenia. Am J Psychiatry. 2000;157:1041-1050.
10. Tsuang MT, Stone WS, Faraone SV. Towards the prevention of schizophrenia. Biol Psychiatry. 2000;48:349-356.
11. Cornblatt BA. The New York high-risk project to the Hillside Recognition and Prevention (RAP) program. Am J Med Genet. 2002;114:956-966.
12. Cornblatt BA, Keilp JG. Impaired attention, genetics, and the pathophysiology of schizophrenia. Schizophr Bull. 1994;20:31-46.
13. Erlenmeyer-Kimling L, Cornblatt B. The New York High-Risk Project: a follow-up report. Schizophr Bull. 1987;13:451-461.
14. Tsuang MT, Stone WS, Faraone SV. Understanding predisposition to schizophrenia: toward intervention and prevention. Can J Psychiatry. 2002;47:518-526.
15. Done DJ, Crow TJ, Johnstone EC, Sacker A. Childhood antecedents of schizophrenia and affective illness: social adjustment at ages 7 and 11. BMJ. 1994;309:699-703.
16. Jones PB, Done DJ. From birth to onset: a developmental perspective of schizophrenia in two national birth cohorts. In: Keshavan MS, Murray RM, eds. Neurodevelopment and Adult Psychopathology, Cambridge, UK: Cambridge University Press; 1997:119-136.
17. Cannon M, Jones P, Huttunen MO, Tanskanen A, et al. School performance in Finnish children and later development of schizophrenia: a population-based longitudinal study. Arch Gen Psychiatry. 1999;56:457-463.
18. David AS, Malmberg A, Brandt L, Allebeck P, Lewis G. IQ and risk for schizophrenia: a population-based cohort study. Psychol Med. 1997;27:1311-1323.
19. Malmberg A, Lewis G, David A, Allebeck P. Premorbid adjustment and personality in people with schizophrenia. Br J Psychiatry. 1998;172:308-313.
20. Cameron DE. Early schizophrenia. Am J Psychiatry. 1938;95:567-678.
21. Kraepelin E. Dementia Praecox and Paraphrenia. Edinburgh, UK: Livingstone; 1919.
22. Meares A. The diagnosis of prepsychotic schizophrenia. Lancet. 1959;1:55-58.
23. Sullivan HS. The onset of schizophrenia. 1927. Am J Psychiatry. 1994;151(suppl):134-139.
24. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull. 1991;17:325-351.
25. Wyatt RJ, Green MF, Tuma AH. Long-term morbidity associated with delayed treatment of first admission schizophrenic patients; a re-analysis of the Camarillo State Hospital data. Psychol Med. 1997;27:261-268.
26. Wyatt RJ, Henter ID. The effects of early and sustained intervention on the long-term morbidity of schizophrenia. J Psychiatr Res. 1998;32:169-177.
27. Haas GL, Garratt LS, Sweeney JA. Delay to first antipsychotic medication in schizophrenia: impact on symptomatology and clinical course of illness. J Psychiatr Res. 1998;32:151-159.
28. Loebel AD, Lieberman JA, Alvir JM, Mayerhoff DI, Geisler SH, Szymanski SR. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry. 1992;149:1183-1188.
29. Craig TJ, Fennig S, Tanenberg-Karant M, Bromet EJ. Rapid versus delayed readmission in first-admission psychosis: quality indicators for managed care? Ann Clin Psychiatry. 2000;12:233-238.
30. Ho BC, Andreasen NC, Flaum M, Nopoulos P, Miller D. Untreated initial psychosis: its relation to quality of life and symptom remission in first-episode schizophrenia. Am J Psychiatry. 2000;157:808-815.
31. Robinson DG, Woerner MG, Alvir JM, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 1999;156:544-549.
32. McGlashan TH. Duration of untreated psychosis in first-episode schizophrenia: marker or determinant of course? Biol Psychiatry. 1999;46:899-907.
33. McGorry PD. Evaluating the importance of reducing the duration of untreated psychosis. Aust N Z J Psychiatry. 2000;34(suppl):S145-S149.
34. Edwards J, McGorry PD. Implementing Early Intervention in Psychosis: A Guide to Establishing Early Psychosis Services. London, UK: Martin Dunitz; 2002.
35. Auther AM, Lencz T, Smith CW, Bowie CR, Cornblatt BA. Overview of the first annual workshop on the schizophrenia prodrome. Schizophr Bull. 2003;29:625-631.
36. Woods SW, Breier A, Zipursky RB, et al. Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biol Psychiatry. 2003;54:453-464.
37. Yung AR, McGorry PD, McFarlane CA, Jackson HJ, Patton GC, Rakkar A. Monitoring and care of young people at incipient risk of psychosis. Schizophr Bull. 1996;22:283-303.
38. Yung AR, Phillips U, Yuen HP, et al. Psychosis prediction: 12-month follow-up of a high-risk ("prodromal") group. Schizophr Res. 2003;60:21-32.
39. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153:321-330.
40. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull. 2000;26:119-136.
41. Marshall M, Lockwood A. Early intervention for psychosis. Cochrane Database Syst Rev. 2004;CD004718.
42. Falloon IR. Early intervention for first episodes of schizophrenia: a preliminary exploration. Psychiatry. 1992;55:4-15.
43. McGorry PD, Edwards J, Mihalopoulos C, Harrigan SM, Jackson HJ. EPPIC: an evolving system of early detection and optimal management. Schizophr Bull. 1996;22:305-326.
44. McGlashan TH, Zipursky RB, Perkins D, et al. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophr Res. 2003;61:7-18.
45. Yung AR, McGorry PD. The initial prodrome in psychosis: descriptive and qualitative aspects. Aust N Z J Psychiatry. 1996;30:587-599.
46. Yung AR, Phillips LJ, McGorry PD, et al. Prediction of psychosis. A step towards indicated prevention of schizophrenia. Br J Psychiatry. 1998;172 (suppl):14-20.
47. McGorry PD, Yung AR, Phillips LJ, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry. 2002;59:921-928.
48. Miller TJ, McGlashan TH, Woods SW, et al. Symptom assessment in schizophrenic prodromal states. Psychiatr Q. 1999;70:273-287.
49. McGlashan TH, Miller TJ, Woods SW, Huffman RE, Davidson L. Instrument for the assessment of prodromal symptoms and states. In: Miller TJ, Mednick SA, McGlashan TH, eds. Early Intervention in Psychotic Disorders. Amsterdam, Netherlands: Kluwer Academic Publishers; 2001:135-149.
50. McGlashan, TH, Zipursky, RB, Perkins, DO, et al. Olanzapine versus placebo for the schizophrenic prodrome: 1-year results. Paper presented at: 156th Annual Meeting of the American Psychiatric Association; May 17-22, 2003; San Francisco, Calif.
51. Arnold SE, Rioux L. Challenges, status, and opportunities for studying developmental neuropathology in adult schizophrenia. Schizophr Bull. 2001;27:395-416.
52. Cornblatt BA, Lencz T, Smith CW, Correll CU, Auther AM, Nakayama E. The schizophrenia prodrome revisited: a neurodevelopmental perspective. Schizophr Bull. 2003;29:633-651.
53. Heinssen RK, Cuthbert BN, Breiling J, Colpe LJ, Dolan-Sewell R. Overcoming barriers to research in early serious mental illness: issues for future collaboration. Schizophr Bull. 2003;29:737-745.
54. Dworkin RH, Cornblatt B, Friedmann R, et al. Childhood precursors of affective vs social deficits in adolescents at risk for schizophrenia. Schizophr Bull. 1993;1993:563-577.
55. Dworkin RH, Lewis JA, Cornblatt BA, Erlenmeyer-Kimling L. Social competence deficits in adolescents at risk for schizophrenia. J Nerv Ment Dis. 1994;182:103-108.
56. Miller TJ, Woods SW, Rosen JL, McGlashan TH. Treatment of psychosis at onset. Am J Psychiatry. 2002;159:153.
57. Yung AR, Phillips LJ, Yuen HP, McGorry PD. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr Res. 2004;67:131-142.
58. an der Heiden W, Hafner H. The epidemiology of onset and course of schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2000;250:292-303.
59. Harrow M, Sands JR, Silverstein ML. Course and outcome for schizophrenia census other psychotic patients: a longitudinal study. Schizophr Bull. 1997;23:287-303.
60. Robinson DG, Woerner MG, McMeniman M, Mendelowitz A, Bilder RM. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004;161:473-479.
61. Strauss JS, Carpenter WT, Jr, Bartko JJ. The diagnosis and understanding of schizophrenia. Part III. Speculations on the processes that underlie schizophrenic symptoms and signs. Schizophr Bull. 1974:61-69.
62. Cornblatt BA, Lencz T, Kane JM. Treatment of the schizophrenia prodrome: is it presently ethical? Schizophr Res. 2001;51:31-38.
63. Hafner H, an der Heiden W. The course of schizophrenia in the light of modern follow-up studies: the ABC and WHO studies. Eur Arch Psychiatry Clin Neurosci. 1999;249(suppl)4:14-26.
64. Cannon M, Walsh E, Hollis C, et al. Predictors of later schizophrenia and affective psychosis among attendees at a child psychiatry department. Br J Psychiatry. 2001;178:420-426.
65. Weiser M, Reichenberg A, Rabinowitz J, et al. Association between nonpsychotic psychiatric diagnoses in adolescent males and subsequent onset of schizophrenia. Arch Gen Psychiatry. 2001;58:959-964.
66. Olin SC, Mednick SA, Cannon T, et al. School teacher ratings predictive of psychiatric outcome 25 years later. Br J Psychiatry. 1998;172(suppl):7-13.
67. Hafner H, Loffler W, Maurer K, Hambrecht M, an der Heiden W. Depression, negative symptoms, social stagnation and social decline in the early course of schizophrenia. Acta Psychiatr Scand. 1999;100:105-118.
68. Beiser M, Erickson D, Fleming JA, Iacono WG. Establishing the onset of psychotic illness. Am J Psychiatry. 1993;150:1349-1354.
69. Miller TJ, Zipursky RB, Perkins D, et al. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample. Schizophr Res. 2003;61:19-30.
70. McGlashan TH, Zipursky RB, Perkins DO, et al. Olanzapine for treatment of the schizophrenia prodrome: 2-year results of a randomized placebo-controlled study. Biol Psychiatry. 2004:55(8S):226S.
71. Hafner H, Maurer K, Ruhrmann S, et al. Early detection and secondary prevention of psychosis: facts and visions. Eur Arch Psychiatry Clin Neurosci. 2004;254:117-128.